Society for Medical Decision Making. Annual meeting. Research Triangle Park NC USA, 1993/10/24.
To compare the costs of alternative strategies for the treatment of duodenal ulcer..
A cost comparison using decision analysis..
A decision model was used to compare the costs per cure of an endoscopically documented duodenal ulcer for three initial treatment strategies : 1) H2-receptor antagonist therapy for 8 weeks, 2) antibiotic therapy for Helicobacter pylori infection plus H2-receptor antagonist therapy, and 3) urease test-based treatment.
For symptomatic recurrences, secondary treatment strategies included empiric retreatment with the same or other regimen, and treatment based on repeat endoscopy-guided urease test or biopsy, with an assumption of subsequent cure.
For all secondary treatment strategies, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist resulted in the lowest average costs per symptomatic cure when the prevalence or likelihood of H. pylori infection exceeded 66% to 76%. The results were not sensitive to the rates of duodenal ulcer recurrence after either treatment, to the cost of either treatment, or to prevalence of H. pylori..
This cost analysis indicates that, regardless of the secondary treatment used for ulcer recurrence, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist provides the lowest costs per symptomatic cure.
Mots-clés Pascal : Ulcère, Duodénum, Helicobacter pylori, Spirillaceae, Spirillales, Bactérie, Coût, Etats Unis, Amérique du Nord, Amérique, Traitement, Homme, Etude comparative, Arbre décision, Appareil digestif pathologie, Intestin pathologie, Bactériose, Infection
Mots-clés Pascal anglais : Ulcer, Duodenum, Helicobacter pylori, Spirillaceae, Spirillales, Bacteria, Costs, United States, North America, America, Treatment, Human, Comparative study, Decision tree, Digestive diseases, Intestinal disease, Bacteriosis, Infection
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0004155
Code Inist : 002B13B03. Création : 01/03/1996.